JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Abroad (travel likely)RecruitingPHASE2

Conditions

Lymphoma, T-Cell · NK-LGL Leukemia · T-LGL Leukemia · Cutaneous T Cell Lymphoma · Cutaneous T Cell Lymphoma (CTCL) · Large Granular Lymphocyte Leukemia · Large Granular Lymphocytic Leukemia · Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract · Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma · Mycosis Fungoides

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology & Blood Diseases Hospital, China, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Shuhua Yi, Doctor) · yishuhua@ihcams.ac.cn · 86-22-23909106
Contact: Study coordinator (Lugui Qiu, Doctor) · qiulg@ihcams.ac.cn · 86-22-23909172
Contact: Principal Investigator (Shuhua Yi, Doctor)
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Lymphoma · Leukemia

Abroad (travel likely)Recruiting

Los Angeles, United States · Bethesda, United States

National Longitudinal Cohort of Hematological Diseases

Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia

Abroad (travel likely)Recruiting

Tianjin, China

CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Lymphoma

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

T-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

New Haven, United States · Boston, United States